Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members see a lot more than you)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
« Previous 1 … 22 23 24 25 26 … 54 Next »

Humira and Enbrel ADA levels and clinical efficacy in psoriasis patients

Threaded Mode
Humira and Enbrel ADA levels and clinical efficacy in psoriasis patients
Fred Offline
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 66,914
Threads: 3,887
Joined: Aug 2011
Gender: Male
Location: France
Psoriatic Arthritis Score: 1
PQOLS: 1
Treatment: Bimzelx / Coconut Oil
#1
News  Sun-11-12-2016, 11:28 AM
This study looked at anti drug antibodies (ADA) levels and clinical efficacy in psoriasis patients using Humira and Enbrel

Quote:
Background:
An algorithm based on measurement of a serum tumour necrosis factor antagonists (anti-TNF) and antidrug antibodies (ADA) has been proposed previously to guide dose escalation or therapy switching in the early (i.e. the first months of) treatment of psoriasis by anti-TNF. In long-term treatment of responding patients with psoriasis, it is usual to empirically reduce standard doses of anti-TNF to reduce exposure while maintaining clinical response. The relationship between serum anti-TNF, ADA levels and clinical efficacy in long-term treated patients with psoriasis has not yet been determined, so the potential role of these parameters in guiding dose escalation in this scenario is unknown.

Aims:
To evaluate the relationship between drug/ADA levels and clinical efficacy in a group of patients with psoriasis undergoing long-term treatment with adalimumab or etanercept.

Methods:
This was a single-centre, prospective, cohort study of patients with psoriasis receiving adalimumab or etanercept for a minimum of 48 weeks. All patients were started on the standard dose, but some adalimumab users had a reduced frequency of administration. Clinical efficacy was measured using the Psoriasis Area and Severity Index. Serum concentrations were measured by ELISA. Clinical assessment and blood sample collection were carried out simultaneously within 24 h before the next drug administration.

Results:
In total, 21 patients were enrolled (67 simultaneous clinical and serum determinations: 38 receiving adalimumab, 29 receiving etanercept). We did not find any association between serum anti-TNF levels and clinical response. None of the patients developed ADA.

Conclusions:
ADA and anti-TNF levels are not related to clinical effectiveness in patients with psoriasis undergoing long-term treatment with adalimumab or etanercept.

Source: onlinelibrary.wiley.com

*Early view funding unknown.

Humira (adalimumab)
Enbrel (etanercept)
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News Efficacy & safety of IL-17 & IL-23 inhibitors in elderly psoriasis patients Fred 1 364 Sat-26-04-2025, 13:22 PM
Last Post: Forest Walker
News Tremfya Japanese safety and efficacy study Fred 0 344 Sat-29-03-2025, 12:33 PM
Last Post: Fred
News Taltz and Japanese patients with psoriasis Fred 0 514 Fri-14-03-2025, 11:49 AM
Last Post: Fred
News Effectiveness of Tremfya in patients with facial and/or genital psoriasis Fred 0 1,341 Fri-28-06-2024, 13:10 PM
Last Post: Fred
News Tremfya and serum protein levels Fred 0 1,223 Thu-09-05-2024, 19:48 PM
Last Post: Fred



Users browsing this thread: 1 Guest(s)
    About | Contact us | Login | Register | Home | Cookies/GDPR | RSS Syndication | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2025 Psoriasis Club | All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB | Social
Linear Mode
Threaded Mode